RA
RVLP

Royce & Associates’s RVL Pharmaceuticals plc Ordinary Shares RVLP Stock Holding History

Royce & Associates’s Portfolio RVLP Stock Details RVLP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-12,115
Closed -$39K – 1057
2021
Q1 		$39K Buy
+12,115
New +$49.8K ﹤0.01% 1011
2020
Q3 		– Sell
-5,012
Closed -$34K – 1191
2020
Q2 		$34K Sell
5,012
-1,172
-19% -$5.74K ﹤0.01% 1080
2020
Q1 		$20K Buy
+6,184
New +$32.9K ﹤0.01% 1091
2019
Q3 		– Sell
-9,479
Closed -$36K – 1192
2019
Q2 		$36K Buy
+9,479
New +$31.5K ﹤0.01% 1063
2019
Q1 		– Sell
-2,745
Closed -$21K – 1200
2018
Q4 		$21K Buy
+2,745
New +$22K ﹤0.01% 1101

Other funds holding RVLP

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
RA
Rovida Advisors Fort Lauderdale, Florida $116M AUM 12.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Squarepoint
Squarepoint New York $46.5B AUM 20.93% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return